Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283395 · ClinicalTrials.gov registry record · Phase 4
Rocklatan® Evaluation
A Phase 4 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 136
- Enrollment target
NCT05283395 is a Phase 4 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 136 participants.
The verdict
NCT05283395, a Phase 4 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 136 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the IOP-lowering effect when subjects are switched from various latanoprost-based regimens to Rocklatan. Subjects will stop their IOP-lowering medical therapy regimen and dose with Rocklatan for the duration of the study (12 weeks).
Interventions
- DRUG Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2023-03-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05283395
The ClinicalTrials.gov registry entry for NCT05283395 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution is the first listed.
NCT05283395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05283395 about?
NCT05283395 is a clinical study titled "Rocklatan® Evaluation". The objective of this study is to evaluate the IOP-lowering effect when subjects are switched from various latanoprost-based regimens to Rocklatan. Subjects will stop their IOP-lowering medical therapy regimen and dose with Rocklatan for the duration of the study (12 weeks).
What is the current status of trial NCT05283395?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 136 participants. The study started on 2022-03-28. Estimated completion is 2023-03-22.
What interventions are being tested in trial NCT05283395?
The interventions under investigation include: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT05283395?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.